The chmp has adopted a negative opinion for omburtamab for the treatment of cns/lm metastasis from neuroblastoma in europe

New york, dec. 16, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the european committee for medicinal products for human use (“chmp”) has adopted a negative opinion recommending a refusal of the marketing authorization for omburtamab for the treatment of cns/leptomeningeal metastasis from neuroblastoma in europe.
YMAB Ratings Summary
YMAB Quant Ranking